Epidemiology Intelligence
Uncover comprehensive Alzheimer's Disease insights in global markets
Clarivate Epidemiology Intelligence provides robust, data-driven insights into Alzheimer’s Disease across global markets, covering mature, emerging, and 126 additional markets via our Extrapolated Worldwide Coverage dashboard.
Our intelligence empowers biopharma teams with insights into:
- Alzheimer’s Disease prevalence data: Global insights across 171 countries from 40+ expert epidemiologists.
- Market sizing & segmentation: Identify growth by disease stage, severity, and treatment status.
- Precision forecasting: Forecast product outcomes by patient subtype and comorbidity.
- Clinical trial optimization: Pinpoint eligible populations and ideal trial sites.
Request more information
What is Epidemiology Intelligence?
Epidemiology Intelligence is your single source of patient population intelligence, featuring a unique combination of incidence and prevalence literature review, in-depth disease-specific forecasts, and U.S. claims-based insights.
Five intuitive use cases
Critical questions explored to inform your strategy
- What is the current and projected prevalence of Alzheimer’s Disease in specific countries and regions?
- How do demographic factors influence the burden of Alzheimer’s Disease?
- What are the treatment patterns and unmet needs within the Alzheimer’s Disease patient population?
- How can understanding Alzheimer’s Disease epidemiology inform strategic decisions in R&D, commercialization, and market access?
10 or 20-year forecasts across 171 countries
Access disease-specific epidemiology with detailed analysis and annualized forecasts to support strategic planning and market assessment.
U.S. claims-based RWD
Gain patient segmentation based on age, gender, ethnicity and location granularity at both the national and state levels with insights from Clarivate U.S. Real-World Data.
Expert-driven disease modeling
Epidemiology forecasts are built by disease specialists using validated methods for confident, data-backed planning.
In-depth epidemiology coverage
Leverage prevalence data to support Alzheimer’s Disease market assessment—developed by a team of 40+ expert epidemiologists.
What’s included in the reports?
- Forecasts through 2033: Patient-based 10-year market outlooks by indication.
- Indication-specific strategy insights: Explore treatment trends, access and reimbursement, unmet needs, and many more.
- Late-phase pipeline intelligence:Track Phase IIb/III assets and timelines to stay ahead of competitors.
- Expert commentary:Interpret data with clarity from our disease analysts, therapy area experts, and epidemiologists.
Spotlight on China In-Depth for Alzheimer’s Disease
What are China In-Depth Reports?
China In-Depth offers comprehensive market intelligence with world-class epidemiology, insight into the China-specific market access landscape, current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:
- Optimize your long-term disease and development strategy in China.
- Quantify market potential for your pipeline assets and those of your
competitors. - Understand current treatment paradigms, the complex access and
reimbursement environment, and the current and future therapeutic
landscape. - Gauge the commercial outlook and impact of key market events.